Teva Pharmaceuticals to acquire BioXcel assets for up to $125m
Teva Pharmaceuticals International has made a bid to acquire a range of neuroscience assets from BioXcel Therapeutics for a total…
News
Lilly’s Mounjaro wins US label expansion for cardiovascular risk reduction
FDA approves Priovant’s rare autoimmune therapy Lisraya in indication first
AusperBio raises $120m to progress hepatitis B therapies
FDA to review Kowa Pharmaceuticals’ NDA for glaucoma eye drop K-911
SK inks $795m Biohaven epilepsy deal, entering potassium channel opener race
ESC 2026: True impact of poor medicine adherence laid bare in hypertensive patients
FDA grants RPDD to ReviR’s RTX-117 for CMT
